11201803009V

Text of the abstract

The invention relates to a CD80 fusion molecule comprising CD80 extracellular domain fused to a human IgG1
Fc domain (CD80-Fc), wherein the CD80-Fc comprises different levels of sialylation with sialic acid residues. The
CD80-Fc comprising sialic acid residues is used for the treatment of cancer, both alone and in combination with
other therapeutic agents including immune stimulating agents such as PD-1/PD-L1 inhibitors.